Alcidion enters $1M partnership with UK hospitals NHS trust
By Meagan Evans. Published at Mar 21, 2019, in Technology
Alcidion Group Limited (ASX: ALC) has been selected as strategic solution partner for Brighton and Sussex University Hospitals NHS Trust in the UK, a contract valued at £574,000 (~A$1.03 million) over five years.
Brighton and Sussex University Hospitals NHS Trust selected Alcidion via a competitive tender process to implement its Patientrack software to improve patient safety and support clinicians in delivering better care.
Patientrack is being used widely by NHS hospitals to capture vital signs and other patient risk factors electronically – at the bedside – improving the timeliness and effectiveness of patient monitoring and improving clinical workflow. Patientrack also uses data analytics to provide doctors and nurses with early warning signs when patients are at risk.
The Trust has an ambitious “best of breed” ICT strategy to support its continuous process of improvement leading to measurable improvements for patients and staff. It has four hospitals, employs approximately 8,200 staff, and delivers specialist and tertiary services for patients from across the south east of England and is also the Major Trauma Centre for the region.
Get our newsletter with an exclusive article straight to your inbox
KEEP ME POSTED
The Trust has a long-term approach to transforming hospital service for the better called the “Patient First Improvement System”, which aims to empower front line staff by equipping them with new tools, methods and a structured process that leads to measurable improvements for patients and staff.
Central to this transformation is the Trust’s role as an academic centre, being a provider of high-quality teaching, and a host hospital for cutting edge research and innovation. On this, it works in partnership with Brighton and Sussex Medical School, Health Education England, Kent, Surrey and Sussex Postgraduate Deanery and the Universities of Brighton and Sussex.
Ian Arbuthnot, the Trust’s director of information management and technology said: ‘Following a thorough selection process, we are very pleased to be working with Alcidion to implement its world-class mobile technology software solution across our hospitals.
“Alcidion’s Patientrack product will provide our clinicians with a solution that allows them to capture patients’ vital signs, automatically calculate the NHS’s NEWS2 (National Early Warning Score) and alert clinicians to deteriorating patients, through mobile devices.
“The system will also deliver a range of patient assessments for conditions such as Sepsis, and Acute Kidney Injury and many more that will reduce the burden of paperwork and deliver real-time information in an integrated patient view at the point of care’.
Alcidion’s Managing Director, Kate Quirke said: “We’re delighted to welcome Brighton and Sussex University Hospitals NHS Trust as a new client and partner. To have another NHS Trust contract with us further solidifies our position as one of the leading suppliers of e-observations and clinical documentation solutions and it is very pleasing to be an integral part of the digital transformation program taking place across the NHS.”
Get our newsletter with an exclusive article straight to your inbox
KEEP ME POSTED
TAGS
TECHMEDTECHASXASX-SMALL CAPS
March 19th
Alcidion wins major UK contract as it looks to help transform healthcare
March 20th
Health Canada decision a key milestone for Roto-Gro
March 18th
CropLogic snares Oregon industrial hemp growers licence
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
Publishers Notice
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.
" class="cls-1" d="M35.6,17.9A17.6,17.6,0,1,1,18,.3,17.6,17.6,0,0,1,35.6,17.9ZM13.5,14.8v2.8h1.9v9.5h3.5V17.6h2.8l.3-2.8H18.9V12.7c0-.7.7-1,1.4-1a7.6,7.6,0,0,1,1.6.2l.4-2.8a13.4,13.4,0,0,0-3.4-.3A3.2,3.2,0,0,0,16,10.2a4.6,4.6,0,0,0-.6,2.8h0v1.7Z">
" class="cls-1" d="M35.6,17.9A17.6,17.6,0,1,1,18,.3,17.5,17.5,0,0,1,35.6,17.9Zm-8.4-6.2a7.9,7.9,0,0,1-2.2.6,3.6,3.6,0,0,0,1.7-2.1,5.4,5.4,0,0,1-2.4.9,4,4,0,0,0-2.8-1.2,3.9,3.9,0,0,0-3.9,3.9c0,.3.1.6.1.9a10.8,10.8,0,0,1-7.9-4.1,4.6,4.6,0,0,0-.5,2A3.7,3.7,0,0,0,11,15.8a5.3,5.3,0,0,1-1.8-.5h0a3.9,3.9,0,0,0,3.1,3.8H10.6a3.8,3.8,0,0,0,3.6,2.6,7.4,7.4,0,0,1-4.8,1.7H8.5a10.8,10.8,0,0,0,16.8-9.2v-.5A6.1,6.1,0,0,0,27.2,11.7Z">
" class="cls-1" d="M35.7,17.9A17.6,17.6,0,1,1,18.1.3,17.6,17.6,0,0,1,35.7,17.9ZM9.6,25h3.8V13.8H9.6ZM11.5,8.3a2,2,0,0,0-2.1,2,1.9,1.9,0,0,0,2.1,1.9h0a1.9,1.9,0,0,0,2.1-1.9A2,2,0,0,0,11.5,8.3Zm11.1,5.2a3.7,3.7,0,0,0-3.4,1.9h0V13.8H15.4c.1,1,0,11.2,0,11.2h3.8V18.7a2.8,2.8,0,0,1,.1-.9,2,2,0,0,1,1.9-1.3c1.4,0,1.9,1,1.9,2.5v6h3.8V18.6C26.9,15.1,25,13.5,22.6,13.5Z">
" id="_Group_">" id="_Compound_Path_">" id="_Compound_Path_2">" id="_Group_2">" id="_Group_3">" id="_Path_">" id="_Group_4">" id="_Path_2">
Get our newsletter sent straight to your inbox
© 2019 Finfeed.com. All Rights Reserved.
The information in this website is general information only. Any advice is general advice only. Your personal objectives, financial situation or needs have not been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice. S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877).
General Discussion / Social Media, page-585
-
- There are more pages in this discussion • 5,640 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
